ライフサイエンスコーパス: hematologic

1 al dysplasia with or without immunologic and hematologic abnormalities, but no definitive metaphyseal

2 sisting of several affected individuals with hematologic abnormalities, including one family member w

3 Grade 3/4 hematologic adverse events were more common with D-RVd.

4 tioning was the probable cause for grade 3-4 hematologic adverse events, as they occurred before CAR-

5 ost common toxicities were grade 3 or higher hematologic adverse events.

6 gastrointestinal, infectious, pulmonary, and hematologic AEs, whereas renal AEs were decreased.

7 ctive (odds ratio, 1.66; 95% CI, 1.19-2.32), hematologic agents (1.75; 95% CI, 1.17-2.62), and IV flu

8 The remaining hematologic and biochemical test results were normal.

9 r analysis focused on 44 clinically relevant hematologic and clinical chemistry measures recorded dur

10 d to determine the safety, tolerability, and hematologic and clinical response.

11 end points of engraftment and safety and for hematologic and clinical responses to treatment.

12 We report on unique hematologic and immunologic parameters that distinguish

13 chotomy between the mechanistic basis of the hematologic and inflammatory components of CD8(+) T cell

14 TC deficiency can produce the hematologic and neurologic complications after birth, wh

15 erapy holds promise for treatment of various hematologic and non-hematologic malignancies, there is e

16 Hematologic and nonhematologic side effects were recorde

17 utoimmune and autoinflammatory diseases, and hematologic and oncologic disorders, giving rise to a ne

18 avenous formulation, and demonstrated robust hematologic and organ responses.

19 ndromes typically associated with underlying hematologic and rheumatic diseases, respectively.

20 ever, it is up-regulated in a diverse set of hematologic and solid malignancies, thus ROR2 represents

21 nical testing as treatments for a variety of hematologic and solid tumor cancers, the results thus fa

22 ematopoietic cell transplants (HCT), cancer (hematologic and solid tumor), HIV, and solid organ trans

23 vity than T1 CAR-T cells against established hematologic and solid tumors in vivo.

24 for exploring SY-1365 in the clinic in both hematologic and solid tumors.

25 rs of age, the plurality of suicides is from hematologic and testicular tumors; if > 50, from prostat

26 low-up were 4,483 (41.3%) skin, 1519 (14.0%) hematologic, and 4842 (44.7%) solid organ.

27 gy.Objectives: To ascertain the physiologic, hematologic, and imaging basis of lung injury in severe

28 ed pattern, n = 6).Conclusions: Physiologic, hematologic, and imaging data show not only the presence

29 dated codes for respiratory, renal, hepatic, hematologic, and neurological failure were used to ident

30 CD25 expression and assess the immunologic, hematologic, and physiologic disease measurement.

31 ls (iPSCs), we have successfully modeled the hematologic aspects of this syndrome in vitro, recapitul

32 dified T cells (CAR-T cells) is effective in hematologic but not epithelial malignancies, which cause

33 (HR, 1.10 [CI, 0.36 to 3.34]), and solid or hematologic cancer (HR, 0.66 [CI, 0.33 to 1.32]).

34 transplantation is indicated for refractory hematologic cancer and some nonmalignant disorders.

35 gnaling, RIN1 inhibited the proliferation of hematologic cancer cell lines and promoted skeletal musc

36 ritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that is caused by transformed plasmac

37 and is associated with an increased risk of hematologic cancer.

38 ginine 882 (DNMT3A(R882mut)) is prevalent in hematologic cancers and disorders.

39 se system to identify activated oncogenes in hematologic cancers in wild-type mice and mice that expr

40 Types of hematologic cancers included 71% (N = 578) lymphoid canc

41 adult cohorts and one pediatric cohort with hematologic cancers taken before, during, and after trea

42 d T-cell therapy is an emerging treatment of hematologic cancers with potential utility in epithelial

43 ls has shown impressive results against some hematologic cancers, but efficacy in solid tumors can be

44 clonal hematopoiesis is an increased risk of hematologic cancers, which has now been shown in several

45 tumor efficacy against established solid and hematologic cancers.

46 to their extremely low abundance compared to hematologic cells.

47 e/female ratio, the involved organs, and the hematologic characteristics.

48 Hematologic complete and very-good-partial response occu

49 eritis nodosa, or giant-cell arteritis) or a hematologic condition (myelodysplastic syndrome or multi

50 (TLR) activation contributes to premalignant hematologic conditions, such as myelodysplastic syndrome

51 based assays tended to show earlier onset of hematologic disease and shorter survival.

52 These results, obtained in diverse hematologic disease entities, show that common targets (

53 ngus, site and extent of IMD, comorbidities, hematologic disease prognosis, and future plans for chem

54 ; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addit

55 lantation (HSCT) is often exploited to treat hematologic disease.

56 The most common ones were hematologic diseases and chromosomal abnormalities.

57 Hematologic diseases may be among the first clinical tar

58 sease (iMCD) is a rare and poorly understood hematologic disorder characterized by lymphadenopathy, s

59 e treatment of multiple myeloma, a malignant hematologic disorder that can produce significant amount

60 >=1 hypomethylating agent for an antecedent hematologic disorder.

61 tic, neurodevelopmental, cardiovascular, and hematologic disorders (8% each); and others.

62 anding indications for HCT to include benign hematologic disorders as well as autoimmune diseases man

63 growing majority of patients diagnosed with hematologic disorders, yet they remain underrepresented

64 at tune hematopoiesis at steady state and in hematologic disorders.

65 ysfunctions differed by small amounts (e.g., hematologic dysfunction 20.1% in cancer-related sepsis v

66 of PAPD5 is a potential strategy to reverse hematologic dysfunction in DC patients.

67 Median hematologic event-free survival (hemEFS) was 11.8 months

68 The hematologic features of HLH were completely dependent on

69 two patients (6%) experiencing grade 3 and 4 hematologic, GI, and genitourinary toxicity, respectivel

70 nfectious (HR, 1.15 [CI, 1.01 to 1.30]), and hematologic (HR, 1.15 [CI, 1.07 to 1.23]) AEs were eleva

71 c multicentric Castleman disease (iMCD) is a hematologic illness involving cytokine-induced lymphopro

72 ticentric Castleman disease (iMCD) is a rare hematologic illness of systemic inflammation and organ d

73 tion between "procedures" and "criteria" for hematologic improvement-erythroid assessment and a new c

74 doses of voxelotor for >=28 days experienced hematologic improvements including increased Hb and redu

75 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), an

76 Hematologic laboratory abnormalities were common (lympho

77 Taking hematologic laboratory data at ~3-month intervals (or as

78 es characterized by dysplasia of one or more hematologic lineages and a high risk of developing into

79 r disease, endocrine/metabolic diseases, and hematologic/lymphoproliferative diseases.

80 lant (SOT; 33.8%), autoimmunity (15.9%), and hematologic malignancies (11.7%).

81 clinical trial of PD-1 blockade for relapsed hematologic malignancies (HMs) after alloHCT (NCT0182250

82 Survivors of childhood hematologic malignancies (HSCT N = 112 [70% allogeneic,

83 C8 (176-406 MBq) into 52 adult patients with hematologic malignancies (lymphoma, multiple myeloma, ac

84 ancies were solid tumors (n = 362; 17.6%) or hematologic malignancies (n = 1,700; 82.4%), including a

85 4905 1-year survivors of allogeneic HCT for hematologic malignancies (N = 4500) or nonmalignant diso

86 th 8% (95% CI, -5% to 19%) for patients with hematologic malignancies (P = .015).

87 ial platelet disorder with predisposition to hematologic malignancies (RUNX1-FPD, FPD/AML, FPDMM); ~4

88 A significant proportion of patients with hematologic malignancies admitted to hospital are admitt

89 ly 35% to 50% of patients otherwise cured of hematologic malignancies after allogeneic hematopoietic

90 with patients with solid tumors, those with hematologic malignancies also experience high rates of h

91 Data regarding associated hematologic malignancies and effective therapies in CANO

92 on worldwide and is associated with numerous hematologic malignancies and epithelial malignancies.

93 suggest a clonal relationship exists between hematologic malignancies and GCTs in these cases.

94 ntly overexpressed in human solid tumors and hematologic malignancies and is associated with tumor ce

95 ent of patients with relapsed and refractory hematologic malignancies and is increasingly investigate

96 ing them with several cancer types including hematologic malignancies and lung cancers, among others.

97 High-throughput sequencing of hematologic malignancies and other cancers has revealed

98 treating human diseases, including solid and hematologic malignancies and parasitic infections.

99 whole-exome and RNA sequencing of these rare hematologic malignancies and present the most complete s

100 l role in the biology of del(20q)-associated hematologic malignancies and revealed a novel molecular

101 remarkable success in treating patients with hematologic malignancies and revitalized the field of ad

102 bined with mAbs are highly effective against hematologic malignancies and solid tumors that are typic

103 e encoding a splicing factor in a variety of hematologic malignancies and solid tumors.

104 he quality of life and care of patients with hematologic malignancies and their caregivers.

105 Patients with hematologic malignancies and those undergoing hematopoie

106 s on hospital mortality of ICU patients with hematologic malignancies and to explore interactions bet

107 Hematologic malignancies are a heterogeneous group of di

108 Furthermore, hematologic malignancies arising in NrasG12D/G12D,C181S

109 Hematologic malignancies arising in this setting genetic

110 orted outcomes in all survivors of childhood hematologic malignancies correlated with the presence of

111 We discovered that GCTs and hematologic malignancies developing in such individuals

112 Patients with hematologic malignancies endure immense physical and psy

113 Patients with hematologic malignancies had higher median viral loads (

114 In addition, patients with hematologic malignancies harbor substantial misperceptio

115 ues report that adult survivors of pediatric hematologic malignancies have high symptom prevalence an

116 tigen receptor (CAR) T cells targeting CD19+ hematologic malignancies have rapidly emerged as a promi

117 large-scale genomic studies in patients with hematologic malignancies identified recurrent somatic al

118 as (B-NHL) represent the most common type of hematologic malignancies in the Western hemisphere.

119 r alpha subunit, CD123, is expressed in many hematologic malignancies including acute myeloid leukemi

120 Cellular therapy for hematologic malignancies is a rapidly evolving field, wi

121 gen receptor (CAR)-modified T cells to treat hematologic malignancies is transforming cancer care for

122 ons for prepubertal children, and women with hematologic malignancies may not be eligible for standar

123 ctive prophylaxis in high-risk patients with hematologic malignancies or hematopoietic cell transplan

124 s in about 5.3% of patients hospitalized for hematologic malignancies receiving chemotherapy.

125 fferent centers that evaluated patients with hematologic malignancies requiring HCT who were randomly

126 Even survivors of hematologic malignancies struggle with late effects, pos

127 rived acute myeloid leukemia (AML) and other hematologic malignancies such as myelofibrosis (MF) in m

128 syndrome is more frequently associated with hematologic malignancies than classic Sweet syndrome.

129 rds in immunophenotyping cell types found in hematologic malignancies to provide an ontological repre

130 Eligible patients had hematologic malignancies treatable by allogeneic HCT.

131 d with cognitive impairment in patients with hematologic malignancies treated with blood or marrow tr

132 risk factors in adult survivors of childhood hematologic malignancies treated with HSCT to those trea

133 Thirty-six patients with hematologic malignancies underwent transplantation at 11

134 rmline mutations in children and adults with hematologic malignancies was previously underappreciated

135 Overt hematologic malignancies were diagnosed in 16 patients (

136 Associated hematologic malignancies were diagnosed in 4 of 33 patie

137 knowledge informs therapeutic approaches for hematologic malignancies with mutant DNMT3A.

138 residents (n = 1,792; 52% allogeneic and 90% hematologic malignancies) were frequency matched by demo

139 ictive strategies are generally supported in hematologic malignancies, acute neurologic injury, and b

140 CD19-directed CAR T cell therapies in B cell hematologic malignancies, advances made in understanding

141 VE was decreased for patients with hematologic malignancies, and there was no significant d

142 erapy has been effective in the treatment of hematologic malignancies, but it has shown limited effic

143 d T cells has generated exciting outcomes in hematologic malignancies, but its application to solid t

144 or (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid t

145 ical syndrome, distinct from de novo GCTs or hematologic malignancies, initiated by an ancestral prec

146 lyzed 9,544 transcriptomes from more than 30 hematologic malignancies, normal blood cell types, and c

147 n oncoproteins are observed in a spectrum of hematologic malignancies, particularly pediatric leukemi

148 clinical activity in relapsed and refractory hematologic malignancies, primarily acute lymphoblastic

149 covered critical effects of SRSF2 mutants in hematologic malignancies, reflecting the regulation at m

150 d as a candidate for clinical development in hematologic malignancies, solid tumors, and gliomas with

151 t-years and were highest in HCT, followed by hematologic malignancies, SOT, and solid tumor malignanc

152 t-years and were highest in HCT, followed by hematologic malignancies, SOT, solid tumor malignancies,

153 ed responses in multiple diseases, including hematologic malignancies, such as Hodgkin lymphoma.

154 for treatment of various hematologic and non-hematologic malignancies, there is essentially no inform

155 emonstrated considerable success in treating hematologic malignancies, they have simultaneously been

156 ase 1 study of 258 patients with IDH1-mutant hematologic malignancies, we report results for 34 patie

157 uppressed patients in contrast to those with hematologic malignancies.

158 lmost exclusively evaluated in patients with hematologic malignancies.

159 nditions, in particular, but not limited to, hematologic malignancies.

160 hort of 15 patients with GCTs and associated hematologic malignancies.

161 ntly consulted for the care of patients with hematologic malignancies.

162 en medically indicated for older adults with hematologic malignancies.

163 promising dual target inhibitor for treating hematologic malignancies.

164 rface markers in order to represent types of hematologic malignancies.

165 notherapy has produced dramatic responses in hematologic malignancies.

166 uction and expansion of T cells for treating hematologic malignancies.

167 of therapeutic agents, active in a number of hematologic malignancies.

168 ed on the surface of cancer cells in several hematologic malignancies.

169 t can personalize care for older adults with hematologic malignancies.

170 t cells have an increased oxidative state in hematologic malignancies.

171 lity of care for older adults diagnosed with hematologic malignancies.

172 sis to facilitate the automated diagnosis of hematologic malignancies.

173 n approaches for multiple myelomas and other hematologic malignancies.

174 p, for expediting therapeutic innovations in hematologic malignancies.

175 genes associated with an increased risk for hematologic malignancies.

176 equent cytogenetic abnormalities detected in hematologic malignancies.

177 h are in clinical use or clinical trials for hematologic malignancies.

178 or (CAR) T cells are a promising therapy for hematologic malignancies.

179 r pathways and candidate drug targets across hematologic malignancies.

180 28-day cycles, in patients with mutant-IDH2 hematologic malignancies.

181 risk of developing AML and CML but no other hematologic malignancies.

182 advances have been made in various areas of hematologic malignancies.

183 Blood transfusion is fundamental in managing hematologic malignancies.

184 on changes implicated in the pathogenesis of hematologic malignancies.

185 oved for the treatment of different types of hematologic malignancies.

186 CAR-T cell therapy is effective for hematologic malignancies.

187 pecially for CAR T cells that target CD19(+) hematologic malignancies.

188 AC) demonstrate efficacy in the treatment of hematologic malignancies.

189 ons and enhance ACT against solid tumors and hematologic malignancies.

190 ed with long-term remission in patients with hematologic malignancies.

191 ICU admission in hospitalized patients with hematologic malignancies.

192 e preferred treatment for many patients with hematologic malignancies.

193 ependence" of Ph+ ALL and, perhaps, of other hematologic malignancies.

194 ic options for single gene disorders and for hematologic malignancies.

195 germ cell tumors (GCTs) in men develop into hematologic malignancies; however, the clonal origins of

196 , and lower risks were noted with underlying hematologic malignancy (HR, 0.29; 95% CI, 0.09-0.98; P =

197 hat cancer drug addiction arises also in the hematologic malignancy ALK-positive anaplastic large-cel

198 Adult patients with hematologic malignancy and COVID-19, especially hospital

199 st 2020 to identify reports of patients with hematologic malignancy and COVID-19.

200 examine the survival of patients who have a hematologic malignancy and multiple organ failure admitt

201 ned to study the survival of patients with a hematologic malignancy and organ failure after admission

202 al nonseminomatous GCTs develop an incurable hematologic malignancy and prior data intriguingly sugge

203 lants between January 1995 and July 2013 for hematologic malignancy and survived at least 100 days.

204 minate potential (CHIP), was associated with hematologic malignancy as well as ASCVD independently of

205 s a criterion for excluding a patient with a hematologic malignancy from admission to the ICU.

206 Historically, patients with a hematologic malignancy have one of the highest mortality

207 Outcomes for patients with hematologic malignancy infected with COVID-19 have not b

208 vasive fungal infections (bIFIs) among adult hematologic malignancy patients and HCT recipients who r

209 influence of the microbiome on the health of hematologic malignancy patients have concentrated on the

210 influence of the microbiome on the health of hematologic malignancy patients have concentrated on the

211 l-life tolerability data in 50 patients with hematologic malignancy receiving >=6 months of ISA.

212 c leukemia (T-ALL) is a highly proliferative hematologic malignancy that results from the transformat

213 Hematologic malignancy was associated with increased COV

214 One-thousand ninety-seven patients with a hematologic malignancy who were admitted at the ICU.

215 ndritic cell neoplasm (BPDCN) is an uncommon hematologic malignancy with poor outcomes.

216 leukemia (AML) is a systemic, heterogeneous hematologic malignancy with poor overall survival.

217 Acute myeloid leukemia (AML) is a deadly hematologic malignancy with poor prognosis, particularly

218 aging, confers a risk of evolution to overt hematologic malignancy, and increases all-cause mortalit

219 Multiple myeloma (MM) is a relatively common hematologic malignancy, and up to half of patients with

220 ncluding during the evaluation of a possible hematologic malignancy, as an incidental discovery durin

221 Multiple myeloma, the second most common hematologic malignancy, frequently relapses because of c

222 e care unit (ICU) admission in patients with hematologic malignancy.

223 to investigate differences based on type of hematologic malignancy.

224 B-cell lymphoma (BCL) is the most common hematologic malignancy.

225 ncer and represents the second most frequent hematologic malignancy.

226 ding and surveillance for the development of hematologic malignancy.

227 optosis induction were additionally shown in hematologic malignant K562 cells, indicating the general

228 The patients underwent thyroid and hematologic monitoring to assess treatment efficacy and

229 SM (advSM), especially SM with an associated hematologic neoplasm (AHN).

230 ture is an important indicator of underlying hematologic neoplasm.

231 paraproteins (31% versus 92%, P = 0.004) and hematologic neoplasms (23% versus 77%, P = 0.02).

232 able paraproteins (31% vs. 92%, P=0.004) and hematologic neoplasms (23% vs. 77%, P=0.02).

233 Non-PGNMID are often associated with hematologic neoplasms and varied prognosis.

234 ypic and polytypic while all 3 patients with hematologic neoplasms had substructure on electron micro

235 pic and polytypic, while all 3 patients with hematologic neoplasms had substructure on electron micro

236 ront treatment stratification for these rare hematologic neoplasms.

237 tablished as a central therapeutic pillar in hematologic oncology.

238 Patients with active hematologic or lung malignancies, peri-COVID-19 lymphope

239 ements have been increasing rates of complex hematologic pain syndromes, present in up to 60% of pati

240 etween fundus abnormalities, VA, or IOP with hematologic parameters (P > 0.05).

241 ocular findings and their relationship with hematologic parameters in TDT patients.

242 The relative stability of the hematologic parameters indicates that blood function and

243 e toxicity by histology, and perturbation of hematologic parameters was transient when observed, retu

244 Clinical and hematologic parameters were collected from the patients'

245 Patients with metabolic and hematologic poisonings were less likely to survive follo

246 mbrane oxygenation was used for metabolic or hematologic poisonings.

247 em cell transplant (HSCT) because of various hematologic problems, including myelosuppression.

248 with respect to complete remission with full hematologic recovery (34% vs. 16%, P<0.001) and with res

249 remission with full, partial, or incomplete hematologic recovery (44% vs. 25%, P<0.001).

250 Complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 42.4% (95% confidenc

251 h excess of blasts, in CR/CR with incomplete hematologic recovery (CRi) after at least 2 cycles of in

252 omplete remission (CR) or CR with incomplete hematologic recovery (CRi) was significantly reduced in

253 ctor (EGF) promoted HSC DNA repair and rapid hematologic recovery in chemotherapy-treated mice and ha

254 Similarly, DJ001 administration accelerates hematologic recovery in mice treated with 5-fluorouracil

255 mice promotes HSC regeneration, accelerates hematologic recovery, and improves survival.

256 a remission rate (RR) of 64% and a very good hematologic remission (VGHR) rate of 48% after 3 months.

257 ients with FLT3-ITD-positive AML in complete hematologic remission after HCT were randomly assigned t

258 AL amyloidosis (n = 30) or AL amyloidosis in hematologic remission for more than 1 y (n = 10).

259 ition in subjects with both active AL and AL hematologic remission.

260 he primary objective was the rate of partial hematologic response (PR) or better.

261 uld be aimed at achieving early and profound hematologic response and organ response in the long term

262 logic response rate was 96%, with a complete hematologic response in 15 (54%) patients; at least part

263 Close monitoring of hematologic response is vital to shifting nonresponders

264 The primary end point was overall hematologic response rate (ORR) by the end of 6 continuo

265 BMDex improved hematologic response rate and overall survival.

266 Hematologic response rate at 3 months was higher in the

267 The primary end point was hematologic response rate at 3 months.

268 Overall hematologic response rate was 96%, with a complete hemat

269 The median time to first and best hematologic response was 4 weeks and 3 months, respectiv

270 Finally, better hematologic response was associated with lower posttreat

271 .2 months (95% CI, 11.3 to 43.8 months), and hematologic response was associated with prolonged survi

272 linical presentation, chemotherapy regimens, hematologic response, and renal and patient outcomes in

273 Age, beta2-microglobulin, best hematologic response, number of cortical casts per squar

274 with overall survival, independently of the hematologic response.

275 progression or up to 6 cycles after complete hematologic response.

276 d AL amyloidosis and leads to rapid and deep hematologic responses and organ responses.

277 lerated and induced molecular remissions and hematologic responses in patients with AML for whom prio

278 apy to induce complete (CR) and partial (PR) hematologic responses in patients with high-risk ET or P

279 During the open-label phase, clinical and hematologic responses were observed in 17 of 19 patients

280 During the open-label phase, clinical and hematologic responses were sustained for 48 weeks in 74%

281 Hematologic responses, 6-month dFLC, organ responses, ov

282 Upfront bortezomib confers durable hematologic responses.

283 primary mediastinal nonseminomas (PMNs) and hematologic somatic-type malignancies (HSTMs).

284 Hematologic, symptomatic, pathologic, and molecular resp

285 ction assay, along with other hemostatic and hematologic tests, was performed 1-3 days before the sur

286 m macroglobulinemia; however, infectious and hematologic toxic effects are problematic.

287 Hematologic toxic effects were the most common events of

288 M6620 with carboplatin, with mechanism-based hematologic toxicities at higher doses, requiring dose d

289 Grade 3 to 4 hematologic toxicities for arm A versus arm B were 13 (4

290 The observed acute hematologic toxicity (5 cases of leukopenia and 2 of thr

291 -PA at diagnosis anticipated greater risk of hematologic toxicity and was independently associated wi

292 Grade 3/4 hematologic toxicity occurred after PRRT in 1 patient (3

293 More frequent hematologic toxicity resulted in more reduced dosing/tre

294 We did not observe any significant hematologic toxicity, and the clinical, biologic, and ul

295 alpha-particle irradiation, with no observed hematologic toxicity.

296 ith STS and offers superior tolerability for hematologic toxicity.

297 common variation in telomere length impacts hematologic traits in the population.

298 Hematologic values pre- and post-oxygenation, respective

299 ncluding demographic, clinical, biochemical, hematologic variables, and extracorporeal membrane oxyge

300 Toxicities were predominantly hematologic, without relevant differences between the 4